Since the release of the EU Annex 1 revision at the end of 2017, the pharma industry has been abuzz about its implications for the global pharma community.

On June 26 at 11:30 a.m., Session 1 of the 3rd PDA Europe Annual Meeting will include three talks addressing topics related to Annex 1. An EMA speaker has been invited to discuss the revision and a representative from the PDA Commenting Team will provide an overview of the team’s comments on the revision. The third speaker will review activities around pre-use/post-sterilization integrity testing (PUPSIT)—a key part of the Annex 1 revision.